Evidence map›Paper›PMID 31025787›Full record

ArticleInternational journal of experimental pathology2019

Absence of the β1 subunit of AMP-activated protein kinase reduces myofibroblast infiltration of the kidneys in early diabetes.

Suet-Wan Choy, Scott A Fraser, Marina Katerelos, Sandra Galic, Bruce E Kemp, Peter F Mount, David A Power

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Suet-Wan ChoyKidney Laboratory, Institute for Breathing and Sleep, University of Melbourne, Heidelberg, Victoria, Australia.
Scott A FraserKidney Laboratory, Institute for Breathing and Sleep, University of Melbourne, Heidelberg, Victoria, Australia.
Marina KaterelosKidney Laboratory, Institute for Breathing and Sleep, University of Melbourne, Heidelberg, Victoria, Australia.
Sandra GalicSt. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
Bruce E KempDepartment of Medicine, University of Melbourne, Austin Health and St. Vincent's Hospital, Heidelberg, Victoria, Australia.
Peter F MountKidney Laboratory, Institute for Breathing and Sleep, University of Melbourne, Heidelberg, Victoria, Australia.
David A PowerKidney Laboratory, Institute for Breathing and Sleep, University of Melbourne, Heidelberg, Victoria, Australia.ORCID 0000-0003-3983-0581
The University of Melbourne · AUSt Vincents Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of the heterotrimeric energy-sensing kinase AMP-activated protein kinase (AMPK) has been reported to improve experimental diabetic kidney disease. We examined the effect of type 1 diabetes in wild-type (WT) mice and mice lacking the β1 subunit of AMPK (AMPK β1

Indexed as

AlbuminuriaAMP-Activated Protein KinasesAnimalsBlood GlucoseCreatinineDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Diabetic NephropathiesKidneyMaleMice, Inbred C57BLMice, KnockoutMyofibroblastsPhosphorylationAMP-Activated Protein KinasesBlood GlucoseCreatinineAMPKdiabetesfibrosismyofibroblast

Identifiers

PMID31025787
PMCPMC6540654
OpenAlexW2940921910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.